Effect of a Unani drug in menopasual transitio
- Conditions
- Health Condition 1: null- Menopausal transition symptoms
- Registration Number
- CTRI/2015/06/005868
- Lead Sponsor
- ational Institute of unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
•Menopausal transition women aged 35 or more
•Presence of any of these symptoms: menstrual changes, hypomenorrhoea, hot flushes, night sweats, sleep disturbances, palpitation, arthralgia, fatigue, anxiety, depression, urinary and sexual problems
•Women with early and late transition: Early transition: changes in cycle length of >=7 days either direction observed for at least two consecutive cycles or 60 days amenorrhoea. Late transition: 90 days to 11 months amenorrhoea.
•Women with known systemic and endocrine diseases like uncontrolled hypertension and diabetes mellitus, thyroid dysfunctions.
•Women with undiagnosed vaginal bleeding, history of surgical menopause.
•Women with hypersensitivity to drugs and past history of taken HRT within two months
•Pregnant and lactating women
•Women with any kind of malignancies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy and safety of the test drug will be assessed by Menopausal Rating Scale (MRS).Timepoint: three months
- Secondary Outcome Measures
Name Time Method Improvement in menstrual irregularities (amenorrhoea, oligomenorrhoea and hypomenorrhoea)Timepoint: three months